Cover Image
市場調查報告書

化療誘發性肢端紅腫症(手足症候群):全球臨床實驗檢討

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2017

出版商 GlobalData 商品編碼 297518
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
化療誘發性肢端紅腫症(手足症候群):全球臨床實驗檢討 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2017
出版日期: 2017年05月31日 內容資訊: 英文 53 Pages
簡介

本報告提供化療誘發性肢端紅腫症(手足症候群)的治療藥相關臨床實驗調查分析,提供臨床實驗數及被實驗人數,Phase別及各方面狀況,有潛力的企業,正在開發的治療藥的資訊,臨床實驗簡介等,為您概述為以下內容。

目錄

簡介

各地區的臨床實驗

  • 各國臨床實驗趨勢
    • 亞太地區的主要國家
    • 歐洲的主要國家
    • 北美的主要國家
    • 中·南美的主要國家

G7各國的臨床實驗:腫瘤科臨床實驗中化療誘發性肢端紅腫症(手足症候群)的比例

G7各國的臨床實驗:Phase別

G7各國的臨床實驗:階段別

E7各國的臨床實驗:腫瘤科臨床實驗中化療誘發性肢端紅腫症(手足症候群)的比例

E7各國的臨床實驗:Phase別

E7各國的臨床實驗:階段別

各方面的臨床實驗

Phase別臨床實驗

評估項目別臨床實驗

未完成的臨床實驗

一定期間所採用的實驗對象

贊助商各類型臨床實驗

有潛力的贊助商

  • 參與化療誘發性肢端紅腫症(手足症候群)治療藥臨床實驗的主要企業

有前途藥物

最新臨床實驗新聞

臨床實驗簡介

  • 主要企業臨床實驗概要
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Cahaba Pharmaceuticals
    • Advancell
  • 主要大學·研究機關·醫院臨床實驗概要
    • Northwestern University
    • Cambridge University Hospitals NHS Foundation Trust
    • Asan Medical Center
    • North Central Cancer Treatment Group
    • Sun Yat-sen University
    • Case Comprehensive Cancer Center
    • Duke University
    • West Virginia University
    • University of California, San Francisco
    • University of Wisconsin Madison

主要的臨床簡介

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4266CTIDB

GlobalData's clinical trial report, "Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2017" provides an overview of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) clinical trials scenario. This report provides top line data relating to the clinical trials on Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Toxicology Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Toxicology Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials by Phase 20
  • In Progress Trials by Phase 21
  • Clinical Trials by Trial Status 22
  • Clinical Trials by End Point Status 23
  • Subjects Recruited Over a Period of Time 24
  • Clinical Trials by Sponsor Type 25
  • Prominent Sponsors 26
  • Top Companies Participating in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials 27
  • Prominent Drugs 28
  • Clinical Trial Profile Snapshots 29

Appendix 51

  • Abbreviations 51
  • Definitions 51
  • Research Methodology 52
  • Secondary Research 52
  • About GlobalData 53
  • Contact Us 53
  • Source 53

List of Tables

List of Tables

  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017* 10
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 13
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 14
  • Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Toxicology Clinical Trials, G7 Countries (%), 2017* 15
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Toxicology Clinical Trials, E7 Countries (%), 2017* 18
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Phase, 2017* 20
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 21
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 22
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 23
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 24
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 25
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 26
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 27
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 28

List of Figures

List of Figures

  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2017* 10
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11
  • Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Toxicology Clinical Trials, G7 Countries (%), 2017* 15
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Toxicology Clinical Trials, E7 Countries (%), 2017* 18
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 20
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 21
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 22
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 23
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 24
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 25
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 26
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 27
  • Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 28
  • GlobalData Methodology 52
Back to Top